
Anuhya Kommalapati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11409425/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers, 2021, 13, 2968.	3.7	63
2	Association between facility volume and mortality of patients with classic Hodgkin lymphoma. Cancer, 2020, 126, 757-764.	4.1	5
3	Second-line therapies in advanced biliary tract cancers. Lancet Oncology, The, 2020, 21, e29-e41.	10.7	77
4	Prevention and treatment of FGFR inhibitor-associated toxicities. Critical Reviews in Oncology/Hematology, 2020, 155, 103091.	4.4	35
5	Personalized Medicine in Advanced Cholangiocarcinoma. Oncology & Hematology Review, 2020, 16, 52.	0.2	1
6	Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leukemia and Lymphoma, 2019, 60, 553-555.	1.3	12
7	FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treatment Reviews, 2019, 78, 1-7.	7.7	57
8	Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 441-446.	0.4	9
9	Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 365-369.	3.6	88
10	Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood, 2018, 131, 265-268.	1.4	73
11	Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 709-720.	4.1	42
12	Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Translational Cancer Research, 2018, 7, S81-S84.	1.0	3
13	Evaluation and management of skeletal disease in cancer care. Critical Reviews in Oncology/Hematology, 2017, 120, 217-226.	4.4	12
14	Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer. Frontiers in Oncology, 2017, 7, 160.	2.8	11
15	Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus, 2017, 9, e1300.	0.5	29
16	Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect. , 2017, 3, 5-6.		0